Welcome to our dedicated page for Microbot Medical SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Microbot Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Microbot Medical's regulatory disclosures and financial reporting.
Microbot Medical Inc. reports that CEO, President and Chairman Harel Gadot will participate in the Society of Robotic Surgery annual meeting in Fort Lauderdale, Florida, held July 23-26, 2026. He will speak on a “Neurovascular Robotics” panel and present an overview of the endovascular robotic market via livestream.
The company notes recent FDA clearance for its single-use LIBERTY® Endovascular Robotic System, describes growing adoption at leading U.S. academic centers for peripheral endovascular procedures, and highlights winning Surgical Robotics Technology’s Innovative Start-Up Award, which recognizes technologically advanced solutions with potential for broad healthcare impact.
Microbot Medical Inc. reports strong commercial momentum for its LIBERTY Endovascular Robotic System in the second quarter of 2026. The company achieved greater than 100% growth in both revenue and new customers for the quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, as procedure volume also increased.
This performance follows the Full Market Release of the LIBERTY System on April 13, 2026, with new adoptions by leading health systems in several U.S. states. Microbot also expanded distribution through an agreement with Lovell Government Services to access federal healthcare systems. The company grew its U.S. sales footprint from 4 to 8 territories during the quarter and aims for 12 by year-end, received marketing clearance in Israel as its first market outside the U.S., and agreed to establish a second manufacturing site to support rising demand.
Microbot Medical Inc. has entered into a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY® Endovascular Robotic System. Sanmina will serve as an additional manufacturing site, giving Microbot more capacity to meet expected demand from existing and new customer accounts.
The company states that expanding manufacturing with a global contract manufacturer is part of its cost reduction strategy. It expects the arrangement to improve operating efficiencies, lower costs, and support higher gross margins as LIBERTY adoption grows in the U.S. and internationally, including Israel and markets where it is pursuing CE Mark and other registrations.
Microbot Medical Inc. filed a current report noting that it has won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY® Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The company reports continued adoption and increased use of LIBERTY following its Full Market Release in early April, including use at leading academic centers across several U.S. states. Management and SRT highlight the system’s innovative design, potential broad healthcare impact, and its aim to improve precision, efficiency, and safety in endovascular care.
Microbot Medical Inc. filed a current report describing new commercial progress for its LIBERTY® Endovascular Robotic System. A globally recognized academic center headquartered in Pennsylvania became the first health system in that state to adopt LIBERTY, joining existing customers in New York City and Boston.
The new customer operates multiple hospitals and multispecialty centers across Pennsylvania and New Jersey, and is the company’s second customer with facilities spanning two states. Microbot now has accounts in seven Eastern U.S. states and, following its recent full market release, plans to expand its sales footprint to the West Coast and further into international markets. A recent agreement expanding access to LIBERTY across certain U.S. federal healthcare systems, including veterans and military patient populations, is also highlighted.
Microbot Medical Inc. has entered into a vendor agreement with Lovell Government Services, creating an opportunity to sell its LIBERTY® Endovascular Robotic System at more than 2,000 U.S. government healthcare facilities, including those of the VA, Department of Defense and Indian Health Service.
Lovell, a Service-Disabled Veteran-Owned Small Business, will list the LIBERTY System on its Federal Supply Schedule contract, with activation expected during the third quarter of 2026, and make it available through platforms such as GSA Advantage, ECAT and DAPA. The relationship is intended to streamline procurement and support broader awareness and adoption across federal healthcare systems.
Microbot Medical Inc. announced that one of the largest healthcare systems in Michigan has become its first Midwest-based account to adopt the LIBERTY Endovascular Robotic System. This follows its first healthcare system customer in North Carolina, showing broader regional uptake across key U.S. markets.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, targeting a U.S. market of approximately 2.5 million procedures annually. The system also recently received regulatory approval in Israel, allowing marketing and sales there as the company advances its full market release strategy.
Microbot Medical Inc. reported a commercial update highlighting new adoption of its LIBERTY® Endovascular Robotic System. The company secured its first North Carolina-based healthcare system customer, described as a leading academic center with a multi-hospital network covering the state.
This new account expands LIBERTY’s geographic footprint from the southeast and mid-Atlantic into the broader northeast and South-Atlantic regions, aligning with Microbot’s commercial strategy following the system’s full market release. The report and accompanying press release also include standard cautionary language about forward-looking statements and refer readers to existing SEC filings for detailed risk factors.
Microbot Medical Inc. reported that Israel’s Ministry of Health AMAR Division has granted regulatory approval for its LIBERTY® Endovascular Robotic System. This approval allows the company to market and commercialize LIBERTY in Israel and obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
Israel is the second jurisdiction, and the first outside the U.S., to grant marketing clearance for LIBERTY. The company is also pursuing CE Mark certification and working toward completion by the end of 2026 to support a planned next phase of commercial expansion into the EU market, while the U.S. remains its primary focus.
Microbot Medical Inc. filed a current report describing plans for an analysts and investors conference call and webcast. The call will be held on Monday, May 18 at 3:00pm ET to review recent progress of the Full Market Release of its LIBERTY Endovascular Robotic System and to address company and product information it says was misrepresented in a recent unaffiliated third-party article. Management, along with two current LIBERTY users, Dr. Charles Briggs and Dr. Zachary Bercu, will discuss real-world experience with the system and respond to described inaccuracies. Access details are available via the company’s investor relations website and a teleconference registration link.